US EditionPublished • loading... • Updated
Interleukin-15 Superagonist Nai Becomes a New Treatment Option for Non-Muscle-Invasive Bladder Cancer
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Amsterdam – People with non-muscle-invasive bladder cancer who have not responded to BCG treatment can now also be treated with the interleukin-15 superagonist nogapendekin alfa inbakicept (NAI). This enhances the immune response against the cancer cells in the bladder wall. The European Medicines Agency (EMA) has...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
